Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01222286 · OUTCOME

Pharmacodynamics of IPH2101

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma · Source last updated 2026-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
% of occupancy of killer like receptor
Interval / dispersion
Full Range
Time frame
from start to end of study (14 months)

What was measured

biological activity of IPH2101 on KIR occupancy at End of Treatment

Analysis population: all subjects who received at least 1 dose of IPH2101

Groups in this outcome

IPH2101 0.2 mg/kg

0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles

IPH2101 2 mg/kg

2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IPH2101 0.2 mg/kg9
IPH2101 2 mg/kg11

Reported measurements

Source class 1
Values in % of occupancy of killer like receptor · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
IPH2101 0.2 mg/kg73.1Not reported4698Not reported
IPH2101 2 mg/kg92Not reported8096Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        46
        upper Limit
        98
        value
        73.1
      2. group Id
        OG001
        lower Limit
        80
        upper Limit
        96
        value
        92
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      11
    units
    Participants
description
biological activity of IPH2101 on KIR occupancy at End of Treatment
dispersion Type
Full Range
groups
  1. description
    0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
    id
    OG000
    title
    IPH2101 0.2 mg/kg
  2. description
    2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
    id
    OG001
    title
    IPH2101 2 mg/kg
param Type
MEAN
population Description
all subjects who received at least 1 dose of IPH2101
reporting Status
POSTED
time Frame
from start to end of study (14 months)
title
Pharmacodynamics of IPH2101
type
SECONDARY
unit Of Measure
% of occupancy of killer like receptor

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice